Expensive brain-cancer drug no longer an option under Medicare
CBSN
Brain-tumor experts and patient advocates are among those decrying a decision by the seller of a cancer drug to exit a federal discount program for Medicare patients, leaving some unable to afford a treatment that can run as much as $1,000 a capsule.
The move by Miami-based NextSource Biotechnology means the drug Gleostine no longer qualifies for Medicare Part D drug assistance, meaning there is one fewer option of a handful of approved chemotherapies. "There are lots of people right now who are not getting the drug," and some will likely die as a result, Henry S. Friedman, a neuro-oncologist and professor of neurosurgery at Duke University School of Medicine, told CBS MoneyWatch. "There are patients who can't afford the drug, and other drugs may not be as effective."Child care in the U.S. today can cost more than families pay for rent, a mortgage or college tuition
The soaring cost of child care in the U.S. can now exceed what families pay for housing or college.
Mexico suggests it could retaliate with tariffs after Trump threat: "There is no subordination here"
President Claudia Sheinbaum suggested Tuesday that Mexico could retaliate ———with tariffs of its own, after U.S. President-elect Donald Trump threatened to impose 25% import duties on Mexican goods if the country doesn't stop the flow of drugs and migrants across the border.
A special agent at the Federal Bureau of Investigation has been charged with sexually assaulting two women, according to police and court records. The agent, Eduardo Valdivia, was previously acquitted of attempted murder for shooting a man on a Metro subway train near Washington, D.C., four years ago. He was arrested in Maryland on Monday.